Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

Antibodies to anti-thymocyte globulin in aplastic anemia patients have a negative impact on hematopoietic SCT

Bone Marrow Transplantation volume 47, pages 1256–1258 (2012)Cite this article

Subjects

Severe aplastic anemia (SAA) is a life threatening BM failure and the preferred therapy for children is allogeneic hematopoietic SCT (HSCT) with an HLA-matched sibling donor. Immunosuppressive therapy with anti-thymocyte globulin (ATG) and CsA is an alternative for patients lacking an HLA-identical donor. For many years, horse ATG (hATG) was the preferred source, but in Europe the production of hATG ended in 2007, and hATG was replaced by rabbit ATG (rATG). Recently, Scheinberg et al.1 published a randomized trial comparing rATG with hATG in SAA patients and concluded that hematological response and survival using hATG was superior to rATG. Here, we report in a pediatric SAA transplant cohort that the use of rATG as first-line therapy, followed by rATG in the HSCT conditioning regimen, can result in severe transplant-related problems.

Sensitization toward ATG, defined as production of anti-ATG Abs, has been observed in SAA patients as well as in solid organ and HSCT recipients.2, 3, 4 When a second immunosuppressive course is required or in vivo T-cell depletion is needed in the context of HSCT, a switch from hATG to rATG is advisable to lower the risk of adverse reactions due to the potential presence of anti-hATG Abs.5

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO et al. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011; 365: 430–438.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Bielory L, Wright R, Nienhuis AW, Young NS, Kaliner MA . Antithymocyte globulin hypersensitivity in bone marrow failure patients. JAMA 1988; 260: 3164–3167.

    Article  CAS  PubMed  Google Scholar 

  3. Prin MC, Renoult E, Kennel De MA, Bene MC, Kessler M, Faure GC . Serum anti-rabbit and anti-horse IgG, IgA, and IgM in kidney transplant recipients. Nephrol Dial Transplant 1997; 12: 2133–2139.

    Article  Google Scholar 

  4. Book BK, Pescovitz MD, Agarwal A, Hardwick LL, Henson SL, Milgrom ML et al. In vitro monitoring of in vivo development of human anti-thymoglobulin antibodies by ELISA. Transplant Proc 2006; 38: 2869–2871.

    Article  CAS  PubMed  Google Scholar 

  5. Marsh JC, Ball SE, Cavenagh J, Darbyshire P, Dokal I, Gordon-Smith EC et al. Guidelines for the diagnosis and management of aplastic anaemia. Br J Haematol 2009; 147: 43–70.

    Article  CAS  PubMed  Google Scholar 

  6. Pullen GR, Fitzgerald MG, Hosking CS . Antibod avidity determination by ELISA using thiocyanate elution. J Immunol Methods 1986; 86: 83–87.

    Article  CAS  PubMed  Google Scholar 

  7. Risitano AM, Selleri C, Serio B, Torelli GF, Kulagin A, Maury S et al. Alemtuzumab is safe and effective as immunosuppressive treatment for aplastic anaemia and single-lineage marrow failure: a pilot study and a survey from the EBMT WPSAA. Br J Haematol 2010; 148: 791–796.

    Article  CAS  PubMed  Google Scholar 

  8. Juliusson G, Theorin N, Karlsson K, Frodin U, Malm C . Subcutaneous alemtuzumab vs ATG in adjusted conditioning for allogeneic transplantation: influence of Campath dose on lymphoid recovery, mixed chimerism and survival. Bone Marrow Transplant 2006; 37: 503–510.

    Article  CAS  PubMed  Google Scholar 

  9. Schmidt-Hieber M, Schwarck S, Stroux A, Ganepola S, Reinke P, Thiel E et al. Immune reconstitution and cytomegalovirus infection after allogeneic stem cell transplantation: the important impact of in vivo T cell depletion. Int J Hematol 2010; 91: 877–885.

    Article  CAS  PubMed  Google Scholar 

  10. Bielory L, Gascon P, Lawley TJ, Nienhuis A, Frank MM, Young NS . Serum sickness and haematopoietic recovery with antithymocyte globulin in bone marrow failure patients. Br J Haematol 1986; 63: 729–736.

    Article  CAS  PubMed  Google Scholar 

  11. Lundquist AL, Chari RS, Wood JH, Miller GG, Schaefer HM, Raiford DS et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 2007; 13: 647–650.

    Article  PubMed  Google Scholar 

  12. Jol-van der Zijde CM, Bredius RGM, Jansen-Hoogendijk AM, Raaijmakers S, Egeler RM, Lankester AC et al. IgG antibodies to ATG early after pediatric hematopoietic stem cell transplantation increase the risk of acute graft versus host disease. Bone Marrow Transplant 2012; 47: 360–368.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Author notes

  1. C M Jol-van der Zijde and R G M Bredius: These author shared first author

Authors and Affiliations

  1. Department of Pediatrics, Leiden University Medical Center (LUMC), Leiden, The Netherlands

    C M Jol-van der Zijde, R G M Bredius, A M Jansen-Hoogendijk, F J Smiers, A C Lankester & M J D van Tol

Authors
  1. C M Jol-van der Zijde
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R G M Bredius
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A M Jansen-Hoogendijk
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F J Smiers
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A C Lankester
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M J D van Tol
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C M Jol-van der Zijde.

Additional information

Author contributions

CJ-vdZ designed and performed the study and prepared the manuscript, RB and MvT designed the study and prepared the manuscript, AJ-H performed the measurements, AL and FS participated in interpretation of data and finalizing the manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jol-van der Zijde, C., Bredius, R., Jansen-Hoogendijk, A. et al. Antibodies to anti-thymocyte globulin in aplastic anemia patients have a negative impact on hematopoietic SCT. Bone Marrow Transplant 47, 1256–1258 (2012). https://doi.org/10.1038/bmt.2011.259

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.259

Search

Advanced search

Quick links